Literature DB >> 6092927

Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs.

L S Ulsh, T Y Shih.   

Abstract

The EJ bladder carcinoma oncogene is activated by a point mutation in the c-rasH proto-oncogene at the 12th amino acid codon. In an attempt to understand the mechanism of oncogenic activation, a comparative study was undertaken to examine the metabolic turnover and subcellular localization of the p21 protein encoded by the EJ oncogene, the viral oncogene, and its normal cellular homolog. Pulse-labeling experiments indicated that both c-ras p21 proteins were synthesized by a very similar pathway, as was observed for the viral p21 protein of Harvey murine sarcoma virus. The pro-p21 proteins were detected in free cytosol, and the processed products were associated with plasma membrane. The intracellular half-life of p21 proteins was determined by pulse-labeling and chasing in the presence of excess unlabeled methionine. Although both p21 proteins of EJ and the normal c-ras genes which are not phosphorylated have a half-life of 20 h, the viral p21 protein of Harvey murine sarcoma virus which includes a phosphorylated form is much more stable in cells, having a half-life of 42 h, apparently due to phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092927      PMCID: PMC368962          DOI: 10.1128/mcb.4.8.1647-1652.1984

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  25 in total

1.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

2.  Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.

Authors:  D J Capon; E Y Chen; A D Levinson; P H Seeburg; D V Goeddel
Journal:  Nature       Date:  1983-03-03       Impact factor: 49.962

3.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

Authors:  C J Der; T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

4.  Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene.

Authors:  Y Yuasa; S K Srivastava; C Y Dunn; J S Rhim; E P Reddy; S A Aaronson
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

5.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

6.  Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

Authors:  E Taparowsky; Y Suard; O Fasano; K Shimizu; M Goldfarb; M Wigler
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

7.  Comparative biochemical properties of p21 ras molecules coded for by viral and cellular ras genes.

Authors:  A Papageorge; D Lowy; E M Scolnick
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

8.  Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses.

Authors:  T Y Shih; P E Stokes; G W Smythers; R Dhar; S Oroszlan
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

9.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

10.  Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1.

Authors:  K Shimizu; D Birnbaum; M A Ruley; O Fasano; Y Suard; L Edlund; E Taparowsky; M Goldfarb; M Wigler
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

View more
  32 in total

1.  Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.

Authors:  M D Sklar; E Thompson; M J Welsh; M Liebert; J Harney; H B Grossman; M Smith; E V Prochownik
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

2.  Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.

Authors:  N Kuzumaki; Y Ogiso; A Oda; H Fujita; H Suzuki; C Sato; L Müllauer
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 3.  Oligonucleotide treatment of ras-induced tumors in nude mice.

Authors:  E Wickstrom
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

4.  Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

Authors:  Reinhard E Marks; Allen W Ho; Christian Robbel; Todd Kuna; Seth Berk; Thomas F Gajewski
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

5.  ras p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function.

Authors:  J C Lacal; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

6.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Authors:  Imanol Arozarena; Fernando Calvo; Piero Crespo
Journal:  Genes Cancer       Date:  2011-03

7.  Positive and negative modulation of H-ras transforming potential by mutations of phenylalanine-28.

Authors:  M H Ricketts; G A Durrheim; H M North; M J van der Merwe; A D Levinson
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

8.  Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man.

Authors:  A K Ghosh; M Moore; M Harris
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

9.  Immunocytochemical localization of ras p21 product in thyroid follicular cells of normal rats using monoclonal antibody RAP-5.

Authors:  Y Mizukami; A Nonomura; T Hashimoto; E Kawahara; S Matsukawa; F Matsubara
Journal:  Histochem J       Date:  1988-11

10.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Authors:  G C Prendergast; J P Davide; S J deSolms; E A Giuliani; S L Graham; J B Gibbs; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.